ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2528

Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States

Min Kim1, Vanessa C. Brunetti1, Felicia Cosman2, Jeffrey Curtis3, E Michael Lewiecki4, Matthew Phelan5, Peter Samai5, Michele McDermott1, Tzu-Chieh Lin1, M Alan Brookhart6 and Kathleen Hurwitz5, 1Amgen, Inc., Thousand Oaks, CA, 2Columbia University, New York, NY, 3University of Alabama at Birmingham, Birmingham, AL, 4New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 5Target RWE, Durham, NC, 6Department of Population Health Sciences, Duke University, Durham, NC

Meeting: ACR Convergence 2023

Keywords: Administrative Data, Fracture, Medicare, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light of this treatment gap, few studies have reported on the incidence of subsequent fracture risk among commercially insured postmenopausal women with a history of fracture.

Methods: We assembled a retrospective cohort of women aged ≥50 years from 2012-2021 using an administrative claims database of privately insured or employer-sponsored Medicare Advantage coverage. Osteoporotic fractures were identified by ≥1 insurance claims with a relevant diagnosis and/or procedure code for an open or closed fracture. Treatments for osteoporosis were identified by prescription fills or medical procedure claims. The cumulative incidence of a new, subsequent fracture at the same or a different anatomic site was estimated for any (clinical vertebral, hip, femur, pelvis, tibia, fibula, radius/ulna/distal forearm, humerus, clavicle, rib, sternum), major (any fracture excluding extremities, clavicle, rib, sternum), hip, and clinical vertebral fractures occurring ≥90 days of initial index fracture to up to 2 years. Women were followed from the index fracture for up to 2 years to estimate the cumulative incidence of any treatment uptake. All analyses used inverse probability weighting to adjust for differential censoring due to differences in demographics and clinical risk factors.

Results: Among the 483,564 women with any initial fracture (mean age 74.8), the 1-year cumulative incidence of a subsequent fracture at any site was 11.6%, which increased to 19.1% at 2 years (Figure). The same-site subsequent fracture risk was highest for women with an initial clinical vertebral fracture: 10.1% experienced a subsequent vertebral fracture at year 1 and 15.9% at year 2. Among women with an initial hip fracture, 12.2% and 19.6% experienced a subsequent fracture at any site after 1 and 2 years, respectively, while 8.0% and 12.2% experienced a subsequent hip fracture at 1 year and 2 years, respectively. Most patients did not receive pharmacological treatment one year (91.7%) and two years (89.4%) after their initial fracture.

Conclusion: Although clinical guidelines specify that OP is a lifelong, chronic disease requiring ongoing management, recent data over a 10-year period show that recurrent fracture rates within 2 years are high, while pharmacological treatment remains underutilized in this high-risk population.

Supporting image 1


Disclosures: M. Kim: Amgen, 3, 11; V. Brunetti: Amgen, 3, 11; F. Cosman: Amgen, 2, 5, 6, Biocon, 2, Enterabio, 2, Radius Health, 2, 5, 6, UCB, 2; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, 5, CorEvitas, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Myriad, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5; E. Lewiecki: Amgen, 2, 5, 6, Ascendis, 6, Radius Health, 2, 5; M. Phelan: Target RWE, 3, 11; P. Samai: NoviSci, 3, 11, Target RWE, 3, 11; M. McDermott: Amgen, 3, 11; T. Lin: Amgen, 3, 3, 3, 11, 11, 11; M. Brookhart: AbbVie/Abbott, 1, Amgen, 1, Atara Biosciences, 1, BlueCross BlueShield North Carolina, 1, Brigham and Women’s Hospital, 1, Fibrogen, 1, Genentech, 1, Merck, 1, National Institutes of Health, 5, NoviSci, 3, 11, Sanofi Pasteur, 1, Target RWE, 3, 11; K. Hurwitz: National Institutes of Health, 5, Target RWE, 3, 11.

To cite this abstract in AMA style:

Kim M, Brunetti V, Cosman F, Curtis J, Lewiecki E, Phelan M, Samai P, McDermott M, Lin T, Brookhart M, Hurwitz K. Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/current-trends-in-the-risk-of-subsequent-fracture-after-initial-fracture-and-post-fracture-treatment-among-commercially-insured-postmenopausal-women-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/current-trends-in-the-risk-of-subsequent-fracture-after-initial-fracture-and-post-fracture-treatment-among-commercially-insured-postmenopausal-women-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology